

Hematopathology Requisition

| Client Information | | Patient Information | |
|--|--|---|--|
| Required Information Account #: Account Name: | | Last Name: | 🔤 Male 🗖 Female |
| Street Address: | | First Name: | M.I Medical Record #: |
| City, ST, ZIP: | | Date of Birth: mm / dd | / yyyy Other Pt ID/Acct #: |
| Phone: Fax: Fax: Fax: | | | d consent from patient to perform the services described herein. |
| | Deter | Specimen Information | |
| Requisition Completed by: Drdering Physician (please print: Last, First): | Date: NPI #: | | Block ID: |
| Treating Physician (please print: Last Eirst): NPI #- | | Fixalive/Preservalive. | |
| By completing this section, the undersigned certifies that he/she is licensed to order the test(s) listed below and that such test(s) are medically necessary for the care/treatment of this patient. | | Collection Date: mm / dd | / yyyy Collection Time: AM D PM |
| uthorized Signature: | | Retrieved Date: mm / dd | |
| | | Hospital Discharge Date: mm | / dd / yyyy |
| Billing Information | | | tasis, list Primary: |
| Required: Please include face sheet and front/back of patient's insurant | | Bone Marrow [must provide CBC | |
| Patient Status (Must Choose 1): □ Hospital Patient (in) □ Hospital Patient (out) □ Non-Hospital Patient Bill to: □ Client Bill □ Insurance □ Medicare □ Medicaid □ Patient/Self-Pay | | Green Top(s) Purple Top(s) Core Biopsy Clot | |
| Split Billing - Client (TC) and Insurance CPC OP Molecular to MCR, all other testing to client | | | Purple Top(s) Other |
| Bill charges to other Hospital/Facility: | | | d): |
| Prior Authorization #See n | | | Other |
| | J | | |
| Clinical Information required: Please attach patient's pathology report (required), clinical hi | stony and other applicable report(a) | | Stained (type of stain) |
| equired: Please attach patient's pathology report (required), clinical hi] ICD 10 (Diagnosis) Code/Narrative (Required): | ыогу, ани опнет аррисарие героп(s). | Slides # Unstained _ Paraffin Block(s) #: | Stained H&E |
| Reason for Referral: | | Paramin Biock(s) #: Choose best block (for glob | |
| □ New Diagnosis □ Relapse/Refractory □ Mon | itoring I MRD | Submit ≤4 blocks. Blocks will be | e combined for molecular testing when necessary. |
| Bone Marrow Transplant (required information for Oncology Cytog | • | For all other testing, specify whi | ich block to use for each if sending multiple blocks. See back for detail |
| None Autologous Allog | , | Comments: | |
| Consultation | | Cytogenetics | |
| OMPASS [®] Comprehensive evaluation including morphology A | NeoGenomics pathologist will select medically necessary | Ancology Chromosome Analysis | |
| Blood and/or Bone Marrow te | sts (with any exceptions noted or marked by the client) provide comprehensive analysis and professional | | is normal (reflex FISH panel must be marked) |
| COMPASS [®] Select (Without morphology) | erpretation for the materials submitted. | Reflex to FISH if cytogenetics | |
| | ease attach CBC for Blood and Bone Marrow equired). | G G T MDS Standard FIS | |
| vmphoma Consult | | | |
| Split fresh specimens to RPMI and formalin | Do not add NGS Profile without prior approval | Specimen Hold Option: Culture | e and Hold (liquid samples & lymph nodes; n/a for solid tissues) |
| Paraffin block for Morphology to follow | | Molecular Genetics | |
| Flow Cytometry Please attach CBC with all flow requests on blood or bone marrow (required). Follow-Up/Add-On panels are available in conjunction with, or after, a Main Panel result has been reported by NeoGenomics or client. | | ABL1 Kinase Domain (Gleevec® | |
| Diagnostia/Bragnostia Banala Add On Tubas | Follow IIn Danole | resistance)* B-Cell Gene Rearrangement | □ FLT3 Mutation Analysis Sequential Reflex to JAK2 Exon 12-13, CALR, & MPL* |
| G T G T G T □ Standard L/L Panel (24 Markers) □ AML □ Extended L/L Panel (31 Markers) □ B-ALL □ N/A CD4/CD8 Ratio for BAL □ CLL/Mantle C | G T D D AML | B-Ceil Gene Rearrangement | |
| Clandard L/L Panel (24 Markers) L L AML AML Extended L/L Panel (31 Markers) L L B-ALL | | BCR-ABL1 Standard p210, p190* | Baseline testing of original NPM1 Mutation Analysis |
| IVA CD4/CD8 Ratio for BAL I □ CLL/Mantle C Erythroid-Meg Erythroid-Meg | | with reflex to ABL1 | primary sample required INPM1 MRD Analysis |
| □ □ T&B Tissue Panel □ □ Hairy Cell | MRD Panels | Kinase Domain if positive BCR-ABL1 Standard p210, p190* | □ IgVH Mutation Analysis* □ PML- RARA, t(15;17)* |
| TRBC1/T-Cell Lymphoma Companion Amat Cell | NA B-ALL MRD Panel (BM) | with reflex to BCR-ABL1 Non- | * □ inv(16) CBFB-MYH11* □ Rapid AML Therapeutic Pane □ JAK2 V617F - Qualitative* □ Molecular only |
| G-Global T-Tech-Only | □ NA B-ALL MRD Panel (PB) □ NA CLL MRD Panel | Standard p230 if negative | ☐ If negative, reflex to JAK2 ☐ RUNX1-RUNX1T1 |
| Specimen Hold Option: Refrigerate and Hold | NA Myeloma (MM) MRD Pane | BCR-ABL1 Non-Standard p230* | Exon 12-13 (AML1-ETO), t(8;21)* |
| ech-Only Opt Out Option: To avoid delay in patient care and as medically neo vill be added by the flow lab when abnormal populations are detected. Please re additional information on tech-only add-on medical necessity criteria. ech-only clients may instruct NeoGenomics to not follow this stated criteria by c | essary for an individual patient, additional markers | BTK Inhibitor Acquired | ☐ If negative, reflex to CALR ☐ T-Cell Receptor Gamma ☐ If negative, reflex to MPL ☐ T-Cell Receptor Beta |
| idditional information on tech-only add-on medical necessity criteria. | hecking this box | Resistance Panel' | □ JAK2 V617F - Quantitative □ TP53 Mutation Analysis |
| FISH G - Global T - Tech-Only | | Calreticulin (CALR) | □ JAK2 Exon 12-13* □ Other |
| ISH G-Global I-lech-Only IemeFISH® Panels G T | GT | CEBPA Mutation Analysis | KIT (c-KIT) Mutation Analysis MPL Mutation Analysis |
| AML Favorable-Risk | N/A High-Grade B-Cell | Specimen Hold Options: T Freeze | e & Hold |
| Anaplastic Large Cell AML Non-Favorable Ri Lymphoma (ALCL) | sk Lymphoma Reflex | If no Possible test is indicated for Extr | ract and Hold option, then Freeze and Hold option will be |
| ALL - Adult Eosinophilia | B-Cell Lymphoma | automatically selected. *Test is not v | • |
| ALL, Ph-Like w/BCL6 (3q27), MYC (8q2 | 4), BCL2 (18q21) MDS Standard | | nsive™ Cancer Profiles G - Global T - with Tech-Only FISH G T |
| □ AML Standard □ Add MYC/IgH/CEN | B t(8;14) | G T N/A AITL/Peripheral T-Cell Lymph | |
| Plasma Cell Myeloma Panels - Plasma Cell Enrichment will be performe marrow samples having plasma cell FISH | | ALL Profile | N/A Lymphoid Disorders Profile |
| | Т | N/A AML Prognostic Profile | □ N/A Lymphoma Profile T3 by PCR* □ N/A MDS/CMML Profile |
| (applies to global only; tech-only will not reflex) | Plasma Cell Myeloma Ign Complex Plasma Cell Myeloma Prognostic Panel | CLL Profile | □ N/A MDS/CMML Profile + FLT3 by PCR* |
| ndividual Probes | etion for D MYC/IgH/CEN8 t(8;14) | Add IgVH Mutation Analy | |
| □ □ 11q Aberration in NHL ALL | D D NUP98 | N/A Neo Comprehensive – Heme | e Cancers + FLT3 by PCR* |
| □ □ ALK for Lymphoma □ □ IgH/MAFB t(14:20) | rangement TCL1 (14q32.1) TP63 Rearrangement | N/A Neo Comprehensive – Myelo N/A Neo Comprehensive – Myelo N/A Neo Comprehensive – Myelo | |
| BCL6/MYC t(3;8) GCK/MYC t(2;8) BCX (API2)/MALT1 t(11;18) GC IGK/MYC t(2;2) | PML/RARA t(15;17) | | fo on Intended Use and Billing for FLT3 by PCR |
| □ □ BIRC3 (API2)/MALT1 t(11;18) □ □ IGL/MYC t(8;22) □ □ BCR/ABL1/ASS1 t(9;22) □ □ JAK2 (9p24.1) | □ □ Other | FlexREPORT® | |

Plasma Cell Enrichment and Hold

| Patient Information | | | | |
|---|---------------------------------------|--|--|--|
| Last Name: [| 🗆 Male 🔲 Female | | | |
| First Name: M.I M | Medical Record #: | | | |
| Date of Birth: mm / dd / yyyy C | d / yyyy Other Pt ID/Acct #: | | | |
| Client represents it has obtained informed consent from patient to perform the services described herein. | | | | |
| Specimen Information | | | | |
| Specimen ID:Block ID: | Block ID: | | | |
| Fixative/Preservative: | | | | |
| | / dd/ yyyy Collection Time: AM D | | | |
| Retrieved Date: mm / dd / yyyy | | | | |
| Hospital Discharge Date: mm/dd/yyyy Body Site: | | | | |
| Primary Metastasis – If Metastasis, list Primary: | | | | |
| Bone Marrow [must provide CBC and Path Report]: | | | | |
| Green Top(s) Core Biopsy Clot | | | | |
| Peripheral Blood: Green Top(s) Purple Top(s) Other | | | | |
| Fresh Tissue (Media Type required): | | | | |
| Fluid: CSF Pleural Other | | | | |
| FNA cell block: | | | | |
| ☐ Smears: Air Dried Fixed Stained (type of stain) ☐ Slides # Unstained Stained □ H&E | | | | |
| | | | | |
| Paraffin Block(s) #: Choose best block (for global molecular/NGS testing on | | | | |
| Submit ≤4 blocks. Blocks will be combined for molecular test | | | | |
| For all other testing, specify which block to use for each if sending multiple blocks. See back for details | | | | |
| Comments: | | | | |
| 1 | | | | |
| Cytogenetics | | | | |
| Reflex to FISH if cytogenetics is normal (reflex FISH panel must be marked) | | | | |
| □ Reflex to FISH if cytogenetics is incomplete (<20 metaphases) | | | | |
| G G T MDS Standard FISH | | | | |
| G T MDS Extended FISH | | | | |
| | | | | |
| Specimen Hold Option: Culture and Hold (liquid samples a | & lymph nodes; n/a for solid tissues) | | | |
| Molecular Genetics | Ivsis D MPN JAK2 V617F with | | | |
| ABL1 Kinase Domain (Gleevec® CXCR4 Mutation Ana resistance)* FLT3 Mutation Analys | | | | |
| □ B-Cell Gene Rearrangement □ IDH1/IDH2 by PCR* Exon 12-13, CALR, & MPL ² | | | | |
| BCR-ABL1 Standard p210, p190* DIGH Clonality by NGS | | | | |
| BCR-ABL1 Standard p210, p190* Baseline testing of o | | | | |

☐ FlexREPORT: Please add summary report option to this case.

For our complete test menu, please visit neogenomics.com/test-menu

Specimen Hold Option: Direct Harvest and Hold

Specimen Requirements

Refrigerate specimen if not shipping immediately and use cool pack during transport. Please call the Client Services team with any questions regarding specimen requirements or shipping instructions at 866.776.5907 option 3. Please refer to the website for specific details on each specimen.

Additional Billing Information

Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

- 1. Binding Service Order. This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
- 2. Third Party Billing by NeoGenomics and Right to Bill Client. Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state or commercial health insurer or other third party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Additional Specimen Information

If submitting multiple blocks, clients must indicate either "Choose best block (global molecular/NGS testing only)", or assign the selection of blocks to individual tests. If multiple blocks are sent without a selection, they will be held until clarification is provided. Please call the Client Services team with any questions regarding specimen information.

Specimen Hold Option Descriptions

To preserve the integrity of samples and avoid unnecessary testing, NeoGenomics Laboratories offers the option of processing samples to maintain specimen integrity for extended periods, without a test order. Any hold order will result in billed charges to the ordering client if testing is not ordered/performed. Specimen Hold Options include:

FISH: Direct Harvest and Hold: FISH specimens will be minimally processed and directly harvested while the cells are still viable. Analysis is not performed until the client test order is received. Processed samples will be retained for 28 days.

Plasma Cell Enrichment and Hold: Plasma cells will be isolated for bone marrow specimens. Sample should be received at NeoGenomics Laboratories within 72 hours of collection. Analysis is not performed until the client test order is received. Processed samples will be retained for 28 days.

Flow Cytometry: Refrigerate and Hold: Flow cytometry samples will be refrigerated and retained for 28 days, however, optimal stability is within 72 hours of collection.

Molecular Testing: Freeze and Hold: Molecular samples will be isolated, preserved using a freezing mix, and stored in a freezer. Use this option when it is uncertain which test(s) may be added. Analysis is not performed until the client test order is received. Processed samples will be retained for 28 days.

Extract Nucleic Acid and Hold: Nucleic acid (DNA or RNA or TNA) will be isolated from viable cells and stored in a freezer. Use this option when it is known which test(s) may be added and make note of which possible tests on test requisition. Analysis is not performed until the client test order is received. Processed samples will be retained for 28 days.

Test Descriptions

Please see complete test descriptions and all available tests at our website, www.neogenomics.com/test-menu.

Test Notations

Specimen Usage

NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

FlexREPORT[®]

FlexREPORT can be ordered on any global or tech-only testing referred to NeoGenomics. This report template can be used to import data and images collected from testing performed outside of NeoGenomics, and incorporated into a one page summary report. Client logo and contact information will be in the header of the FlexREPORT.

FISH

Plasma cell myeloma FISH panels: Plasma cell enrichment will be performed on bone marrow samples having plasma cell FISH. Sample should be received at NeoGenomics Laboratories within 72 hours of collection.

FLT3 Testing with NeoTYPE and Neo Comprehensive profiles

The FLT3 Mutation Analysis test is available as client-bill only when ordered with NeoTYPE and Neo Comprehensive. The Molecular case reports separately from the NeoTYPE or Neo Comprehensive Profile (which also includes FLT3 gene by NGS) for the purpose of prompt therapy selection in patients with a *new* diagnosis of AML.